Contract analysis

I. Purpose and Executive Summary This memorandum analyzes the pre-filing correspondence between Penterra Pharmaceuticals Corp. ("Penterra" or "PPC") and Vantage Medical Distribution, LLC ("Vantage" or "VMD") and evaluates the viability of Vantage's threatened counterclaims in light of the Exclusive Distribution Agreement dated July 1, 2017 (the "EDA" or the "Agreement"). The purpose of this analysis is to provide Lin

II. Background Facts A. The Parties

1. Penterra Pharmaceuticals Corp. Penterra Pharmaceuticals Corp. is a Delaware corporation, publicly traded on the Nasdaq Stock Market under the ticker symbol PTRA. The company maintains its principal headquarters at 400 Carnegie Center Drive, Suite 600, Princeton, New Jersey 08540. Penterra is a mid-cap specialty pharmaceutical company with a commercial focus in three therapeutic areas: oncology, rare diseases, and

2. Vantage Medical Distribution, LLC Vantage Medical Distribution, LLC is a limited liability company organized under the laws of the Commonwealth of Massachusetts. Its principal office is located at 75 Cabot Road, Suite 310, Medford, Massachusetts 02155. Vantage is a regional specialty pharmaceutical distributor founded in 2009 by Donald R. Farnham. The company focuses on distributing branded specialty pharmaceutica

Section 2.1 — Grant of Exclusive Territory. This section provides: "Supplier hereby grants to Distributor the exclusive right to distribute the Products within the Territory, as defined in Exhibit A." The grant is explicitly tied to, and limited by, the definition of "Territory" set forth in Exhibit A. Exhibit A — Territory Definition. Exhibit A states in full: "The states of Connecticut, Maine, Massachusetts, New Ha

Section 2.3 — Limitation. This section provides: "Distributor shall not actively solicit orders for, or deliver, the Products outside the Territory without Supplier's prior written consent." This provision establishes a clear prohibition on out-of-territory activity and makes any expansion conditional on Penterra's affirmative, written authorization. The phrase "prior written consent" implies a deliberate, specific a

Section 5.2 — Minimum Annual Purchase Commitment. This section establishes a minimum annual purchase commitment for Oncalaris® of $9.5 million per year at wholesale acquisition cost (WAC). As discussed below, Vantage has exceeded this minimum in every year of the Agreement's term.

Section 13.1 — Amendments. This section provides: "No amendment, modification, or waiver of any provision of this Agreement shall be effective unless set forth in a written instrument signed by both parties." This is a standard anti-oral-modification clause, and its enforceability under Massachusetts law is well established. The provision requires dual-signature written instruments — not emails, not oral representati

Section 14.2 — Governing Law. The Agreement is governed by the laws of the Commonwealth of Massachusetts, without regard to conflicts of law principles.

Section 14.5 — Dispute Resolution. The parties have consented to the exclusive jurisdiction of the state or federal courts located in the Commonwealth of Massachusetts for the resolution of any dispute arising under or in connection with the Agreement.

Section 14.8 — Entire Agreement / Integration Clause. This section provides: "This Agreement, including all Exhibits, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior negotiations, representations, or agreements relating thereto, whether written or oral." This is a standard integration clause that bars the introduction of extrinsic evidence to var

III. Analysis of Penterra's March 8, 2021 Cease-and-Desist Letter A. Summary of the Letter's Content The cease-and-desist letter, dated March 8, 2021, was authored by Jennifer Chao, Penterra's General Counsel, and addressed to Donald R. Farnham in his capacity as Managing Member and CEO of Vantage Medical Distribution, LLC. A copy of the letter is attached as Appendix A. The letter contains the following substantive

1. Identification of the Contractual Violation. The letter identifies Vantage's distribution of Oncalaris® in the states of New York, New Jersey, and Pennsylvania as a violation of Section 2.3 of the EDA, which prohibits the Distributor from actively soliciting orders for, or delivering, the Products outside the Territory without Supplier's prior written consent.

2. Demand for Cessation. The letter demands that Vantage immediately cease all distribution, solicitation, and delivery of Oncalaris® outside the six New England states defined in Exhibit A to the EDA.

3. Compliance Deadline. The letter sets a deadline of March 22, 2021 — fourteen days from the date of the letter — for Vantage to confirm in writing that it has ceased all tri-state distribution activities and that no further shipments outside the Territory will occur.

4. Reservation of Rights. The letter expressly reserves all of Penterra's rights and remedies under the Agreement and at law, including, without limitation, the right to seek damages, injunctive relief, termination of the Agreement, or any other relief to which Penterra may be entitled. B. Assessment of the Letter's Legal Sufficiency The cease-and-desist letter is a well-drafted instrument that serves its intended pu

IV. Analysis of Vantage's March 22, 2021 Response Letter A. Summary of the HSP Letter's Content On March 22, 2021 — the same day as the compliance deadline set by Penterra's cease-and-desist letter — Kenneth M. Rourke, lead partner at Hargrove, Sinclair & Polk LLP (200 Ashbury Asset Advisors, Suite 1800, Boston, Massachusetts 02109), sent a seven-page letter to Jennifer Chao on behalf of Vantage. A copy of the HSP le

1. Kapoor Email as "Prior Written Consent" (Section 2.3) Vantage's primary legal theory is that the January 12, 2018 Kapoor Email constitutes the "prior written consent" required by Section 2.3 of the EDA for distribution outside the Territory. This argument is, in our assessment, weak and unlikely to succeed under Massachusetts contract interpretation principles. The email's language is plainly forward-looking and c

2. Course of Dealing / Implied Modification Vantage's secondary legal theory is that Penterra's failure to object to Vantage's out-of-territory shipments over an extended period effected an implied modification of Exhibit A, expanding the Territory to include New York, New Jersey, and Pennsylvania. This theory faces formidable contractual and doctrinal obstacles under Massachusetts law. Written-amendment clause (Sect

3. Assessment of the $35 Million Counterclaim Threat The HSP letter threatens a $35 million counterclaim but does not provide a breakdown of the figure or a methodology for its calculation. Based on our preliminary analysis, the $35 million likely encompasses some combination of: (a) lost future profits from tri-state distribution (projected over the remaining term of the EDA and potential renewal periods), (b) loss

V. Strategic Considerations A. Risks and Vulnerabilities While Penterra holds a strong contractual position, litigation outcomes are never certain, and we identify the following risks and vulnerabilities that warrant careful management: Timing of objection. As noted above, the approximately six-month gap between Vantage's commencement of tri-state shipments (on or about September 14, 2020) and the cease-and-desist le

Section 14.5 of the EDA provides for the exclusive jurisdiction of state or federal courts located in the Commonwealth of Massachusetts. This forum-selection clause is enforceable and should be invoked by Penterra to ensure that the dispute is litigated in a favorable and convenient forum. We recommend filing the Complaint for Declaratory Judgment in the Superior Court of Massachusetts, Business Litigation Session, S

VI. Recommended Litigation Strategy A. Immediate Steps Based on the foregoing analysis, we recommend the following immediate actions:

1. File a Complaint for Declaratory Judgment. Penterra should file a Complaint for Declaratory Judgment in the Superior Court of Massachusetts, Business Litigation Session, Suffolk County, pursuant to G.L. c. 231A. The complaint should seek a declaration that: (a) the Territory under the EDA is limited to the six New England states defined in Exhibit A (Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island,

2. Issue a litigation hold notice. Penterra should issue a litigation hold notice to all personnel with potentially relevant knowledge or documents. Key custodians include: Dr. Marcus Lindholm (CEO), Jennifer Chao (General Counsel), Steven Kapoor (VP, Commercial Operations), Rachel Mendez (Director of Distribution & Logistics), and any other personnel involved in the Vantage relationship, the Kapoor Email exchange, o

3. Preserve and collect key documents. The following documents should be immediately preserved and collected for litigation: (a) The January 12, 2018 Kapoor Email and the complete surrounding email chain or thread, including any attachments, forwards, or replies; (b) All communications between Penterra and Vantage personnel regarding the Territory, potential territorial expansion, tri-state distribution, and the Meri